Immunocore Holdings plc
Index- P/E- EPS (ttm)-3.85 Insider Own22.54% Shs Outstand43.86M Perf Week-1.51%
Market Cap1.22B Forward P/E- EPS next Y-243.01 Insider Trans0.00% Shs Float33.01M Perf Month-15.28%
Income-163.90M PEG- EPS next Q-65.49 Inst Own46.00% Short Float3.47% Perf Quarter26.36%
Sales33.00M P/S37.06 EPS this Y-76.70% Inst Trans11.66% Short Ratio5.92 Perf Half Y-21.60%
Book/sh4.87 P/B5.90 EPS next Y0.50% ROA-38.50% Target Price53.50 Perf Year-26.01%
Cash/sh6.96 P/C4.13 EPS next 5Y- ROE-62.50% 52W Range18.43 - 42.25 Perf YTD-16.15%
Dividend- P/FCF- EPS past 5Y- ROI-53.40% 52W High-32.05% Beta-
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low55.78% ATR2.15
Employees324 Current Ratio4.30 Sales Q/Q-10.80% Oper. Margin- RSI (14)42.87 Volatility5.67% 7.80%
OptionableYes Debt/Eq0.37 EPS Q/Q-101.20% Profit Margin- Rel Volume1.17 Prev Close29.53
ShortableYes LT Debt/Eq0.36 Earnings- Payout- Avg Volume193.46K Price28.71
Recom1.70 SMA20-6.49% SMA50-8.89% SMA200-8.85% Volume226,065 Change-2.78%
Feb-08-22Initiated H.C. Wainwright Buy $80
Oct-20-21Initiated Oppenheimer Outperform $56
Mar-02-21Initiated JP Morgan Overweight $58
Mar-02-21Initiated Jefferies Buy $65
Mar-02-21Initiated Goldman Neutral $40
May-23-22 07:24AM  
May-21-22 08:00AM  
May-11-22 07:00AM  
May-03-22 09:28AM  
May-02-22 10:45AM  
Apr-07-22 07:00AM  
Apr-06-22 07:01AM  
Apr-04-22 11:05AM  
Apr-01-22 09:00PM  
Mar-16-22 12:00PM  
Mar-09-22 05:30PM  
Mar-03-22 07:00AM  
Feb-25-22 02:00AM  
Feb-11-22 07:00AM  
Jan-26-22 12:15PM  
Jan-06-22 07:00AM  
Dec-06-21 07:00AM  
Nov-11-21 07:00AM  
Nov-10-21 07:00AM  
Nov-09-21 08:01AM  
Nov-01-21 09:07AM  
Oct-18-21 07:30AM  
Sep-22-21 06:00PM  
Sep-20-21 07:00AM  
Sep-13-21 04:30PM  
Sep-10-21 07:00AM  
Sep-08-21 07:00AM  
Aug-24-21 07:00AM  
Aug-11-21 07:00AM  
Jul-27-21 07:00PM  
Jun-04-21 09:05AM  
May-28-21 08:06PM  
May-27-21 04:30PM  
May-18-21 04:10PM  
May-12-21 07:00AM  
May-05-21 07:42AM  
Apr-28-21 04:30PM  
Apr-22-21 05:52AM  
Apr-12-21 04:30PM  
Mar-25-21 07:00AM  
Mar-10-21 07:00PM  
Feb-19-21 07:00AM  
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.